Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial

IMPORTANCE: Current treatment options for progressive ovarian cancer provide limited benefit, particularly in patients whose disease has become resistant to platinum-based chemotherapy. OBJECTIVE: To assess the efficacy and safety of avelumab, an anti–programmed death-ligand 1 agent, in a cohort of...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JAMA Oncol
Principais autores: Disis, Mary L., Taylor, Matthew H., Kelly, Karen, Beck, J. Thaddeus, Gordon, Michael, Moore, Kathleen M., Patel, Manish R., Chaves, Jorge, Park, Haeseong, Mita, Alain C., Hamilton, Erika P., Annunziata, Christina M., Grote, Hans Juergen, von Heydebreck, Anja, Grewal, Jaspreet, Chand, Vikram, Gulley, James L.
Formato: Artigo
Idioma:Inglês
Publicado em: American Medical Association 2019
Assuntos:
Original Investigation
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6439837/
https://ncbi.nlm.nih.gov/pubmed/30676622
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2018.6258
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados